Molly Harper
Director/Board Member at CATALYST PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-05-30
Molly Harper active positions
Companies | Position | Start | End |
---|---|---|---|
CATALYST PHARMACEUTICALS, INC. | Director/Board Member | 2021-06-28 | - |
Independent Dir/Board Member | 2021-06-28 | - |
Career history of Molly Harper
Former positions of Molly Harper
Companies | Position | Start | End |
---|---|---|---|
SYNLOGIC, INC. | Corporate Officer/Principal | 2021-09-26 | 2023-12-31 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
PreciseDx Ltd.
PreciseDx Ltd. Data Processing ServicesTechnology Services PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021. | Director/Board Member | 2022-03-14 | - |
RELMADA THERAPEUTICS, INC. | Chief Operating Officer | 2020-05-25 | - |
Training of Molly Harper
Cornell University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
United States | 8 |
United Kingdom | 2 |
Operational
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chief Operating Officer | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
RELMADA THERAPEUTICS, INC. | Health Technology |
CATALYST PHARMACEUTICALS, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Private companies | 3 |
---|---|
PreciseDx Ltd.
PreciseDx Ltd. Data Processing ServicesTechnology Services PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021. | Technology Services |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Molly Harper
- Experience